Department of Otorhinolaryngology, Keimyung University School of Medicine, Daegu, Korea
Copyright © 2017 by The Korean Balance Society. All rights reserved.
This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Author | Study design | Gene | Objective | Subjects | Ancestry | Association |
---|---|---|---|---|---|---|
Koyama et al. [26] | Case-control | HLA-Cw04 | Susceptibility | 20/20 | Asian | No |
DRB1*1602 | Yes | |||||
Melchiorri et al. [27] | Case-control | HLA-Cw07 | Susceptibility | 41/34/101 | Caucasian | Yes |
Lopez-Escamez et al. [28] | Case-control | HLA- | Susceptibility | 54/534 | Caucasian | No |
Lopez-Escamez et al. [29] | Case-control | HLA-DRB1*1101 | Susceptibility | 80/250 | Caucasian | Yes |
Khorsandi et al. [30] | Case-control | HLA-Cw04 | Susceptibility | 22/91 | Caucasian | Yes |
Klar et al. [31] | Familial | 12p12 | Susceptibility | 13/8 | Caucasian | Yes |
PIK3C2G | ||||||
Hietikko et al. [32] | Familial | 12p12.3 | Susceptibility | 16 families | Caucasian | No |
Arweiler-Harbeck et al. [33] | Familial | Chromosome 5 | Susceptibility | 52/29 | Caucasian | Yes |
Yazdani et al. [34] | Case-control | MIF-173 | Susceptibility | 72/100 | Caucasian | Yes |
Gazquez et al. [35] | Case-control | MIF, INFG, TFNA | Susceptibility | 580/552 | Spanish/American | No |
Mhatre et al. [36] | Case-control | AQP2 | Mutationa’s analysis | 12 | American | No |
Candreia et al. [37] | Case-control | AQP3 | Mutationa’s analysis | 34/100 | Caucasian | No |
Maekawa et al. [7] | Case-control | AQP2 | Gene expression study | 15/9 | Asian | No |
Lynch et al. [38] | Case-control | AQP1 | Mutationa’s analysis | 14 | Australian | No |
Doi et al. [39] | Case-control | KCNE1–3 | Susceptibility | 63/237 | Asian | Yes |
Campbell et al. [40] | Case-control | KCNE1–3 | Susceptibility | 180/180 | Caucasian | No |
Hietikko et al. [41] | Case-control | KCNE1 | Mutationa’s analysis | 59/98 | Caucasian | Yes |
Teggi et al. [42] | Case-control | ADD1 | Susceptibility | 28/48 | Caucasian | Yes |
Kawaguchi et al. [43] | Case-control | HSPA1A | Susceptibility | 49/100 | Asian | Yes |
Vrabec et al. [44] | Case-control | HCFC1 | Susceptibility | 21/33 | Caucasian | No |
Lopez-Escamez et al. [45] | Case-control | PTPN22 | Susceptibility | 52/348 | Caucasian | Yes |
Furuta et al. [46] | Case-control | IL1A | Susceptibility | 68/72/2202 | Asian | Yes |
Lopez-Escamez et al. [47] | Case-control | CD16A/CD32 | Susceptibility | 156/626 | Caucasian | No |
Gazquez et al. [48] | Case-control | NOS1–NOS2A | Susceptibility | 273/550 | Caucasian/American | No |
Lopez-Escamez et al. [49] | Case-control | PARP-1 | Susceptibility | 80/371 | Spanish | No |
Author | Study design | Gene | Objective | Subjects | Ancestry | Association |
---|---|---|---|---|---|---|
Koyama et al. [26] | Case-control | HLA-Cw04 | Susceptibility | 20/20 | Asian | No |
DRB1*1602 | Yes | |||||
Melchiorri et al. [27] | Case-control | HLA-Cw07 | Susceptibility | 41/34/101 | Caucasian | Yes |
Lopez-Escamez et al. [28] | Case-control | HLA- | Susceptibility | 54/534 | Caucasian | No |
Lopez-Escamez et al. [29] | Case-control | HLA-DRB1*1101 | Susceptibility | 80/250 | Caucasian | Yes |
Khorsandi et al. [30] | Case-control | HLA-Cw04 | Susceptibility | 22/91 | Caucasian | Yes |
Klar et al. [31] | Familial | 12p12 | Susceptibility | 13/8 | Caucasian | Yes |
PIK3C2G | ||||||
Hietikko et al. [32] | Familial | 12p12.3 | Susceptibility | 16 families | Caucasian | No |
Arweiler-Harbeck et al. [33] | Familial | Chromosome 5 | Susceptibility | 52/29 | Caucasian | Yes |
Yazdani et al. [34] | Case-control | MIF-173 | Susceptibility | 72/100 | Caucasian | Yes |
Gazquez et al. [35] | Case-control | MIF, INFG, TFNA | Susceptibility | 580/552 | Spanish/American | No |
Mhatre et al. [36] | Case-control | AQP2 | Mutationa’s analysis | 12 | American | No |
Candreia et al. [37] | Case-control | AQP3 | Mutationa’s analysis | 34/100 | Caucasian | No |
Maekawa et al. [7] | Case-control | AQP2 | Gene expression study | 15/9 | Asian | No |
Lynch et al. [38] | Case-control | AQP1 | Mutationa’s analysis | 14 | Australian | No |
Doi et al. [39] | Case-control | KCNE1–3 | Susceptibility | 63/237 | Asian | Yes |
Campbell et al. [40] | Case-control | KCNE1–3 | Susceptibility | 180/180 | Caucasian | No |
Hietikko et al. [41] | Case-control | KCNE1 | Mutationa’s analysis | 59/98 | Caucasian | Yes |
Teggi et al. [42] | Case-control | ADD1 | Susceptibility | 28/48 | Caucasian | Yes |
Kawaguchi et al. [43] | Case-control | HSPA1A | Susceptibility | 49/100 | Asian | Yes |
Vrabec et al. [44] | Case-control | HCFC1 | Susceptibility | 21/33 | Caucasian | No |
Lopez-Escamez et al. [45] | Case-control | PTPN22 | Susceptibility | 52/348 | Caucasian | Yes |
Furuta et al. [46] | Case-control | IL1A | Susceptibility | 68/72/2202 | Asian | Yes |
Lopez-Escamez et al. [47] | Case-control | CD16A/CD32 | Susceptibility | 156/626 | Caucasian | No |
Gazquez et al. [48] | Case-control | NOS1–NOS2A | Susceptibility | 273/550 | Caucasian/American | No |
Lopez-Escamez et al. [49] | Case-control | PARP-1 | Susceptibility | 80/371 | Spanish | No |